Ronald Scott, CEO of Basilea, a biotech company that was spun out of Roche in 2000, talks about launching its first two products, Zevtera and Cresemba; the milestone agreement with the Biomedical Advanced Research and Development Authority (BARDA) to develop Zevtera for the US market; and about the company’s partnering strategy for the development of its oncology portfolio.
Could you start by giving our readers an overview of Basilea, a company that was spun-off from Roche 16 years ago?
There is a very significant medical need related to overcoming the development of resistance. It is a continual challenge, both in the area of anti-infectives, as well as in oncology
